These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29426696)

  • 1. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
    da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
    Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.
    Minardi D; Lucarini G; Milanese G; Montironi R; Di Primio R
    Virchows Arch; 2017 Jul; 471(1):99-105. PubMed ID: 28488170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
    Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Milanese G; Di Primio R; Montironi R; Muzzonigro G
    Urol Oncol; 2016 Aug; 34(8):338.e11-8. PubMed ID: 27085487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
    Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
    J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
    Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
    Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.
    da Costa WH; Rezende M; Carneiro FC; Rocha RM; da Cunha IW; Carraro DM; Guimaraes GC; de Cassio Zequi S
    BJU Int; 2014 May; 113(5b):E157-63. PubMed ID: 24053427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma.
    Nam SJ; Lee C; Park JH; Moon KC
    Urol Oncol; 2015 Aug; 33(8):340.e9-16. PubMed ID: 26003625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
    Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
    Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
    Oka S; Inoshita N; Miura Y; Oki R; Miyama Y; Nagamoto S; Ogawa K; Sakaguchi K; Kondoh C; Kurosawa K; Urakami S; Takano T; Okaneya T
    Urol Oncol; 2018 Aug; 36(8):365.e9-365.e14. PubMed ID: 29853346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
    Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
    Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
    Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
    Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.